Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Optune (TTFields, 200 kHz) Concomitant With Maintenance TMZ and Pembrolizumab Versus Optune Concomitant With Maintenance TMZ and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2026 According to Novocure Limited media release, enrollment completion in this study is expected in Q4 2026.
02 May 2024 According to a Novocure media release, in March, the FDA approved the Investigational New Drug (IND) application for this trial.
30 May 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com